M

Mallinckrodt

Specialty pharmaceutical developer, manufacturer, distributor

Patient Access Manager

Full-Time
$111k - $178k+ Bonus
Senior, Expert
Bachelor's, Master's, MBA, PhD
Malvern, PA, USA+2 moreMore locations: Bridgewater, NJ, USA | Hazelwood, MO, USA
RemoteFully remote; up to 30% travel may be required.
Medical, Clinical & VeterinaryClinical Support & Patient Administration

About the job

Requirements
  • A Bachelor of Science degree or equivalent is required.
  • Eight to ten years of relevant experience in the biopharmaceutical industry is required.
  • Five years of reimbursement experience is required.
  • Demonstrated expertise resolving highly complex reimbursement, affordability, and access challenges across multiple payer channels.
  • Ability to influence outcomes across cross-functional stakeholders without direct authority.
  • Experience identifying systemic access trends and translating observations into actionable business recommendations.
  • Systemic understanding of the global payer and distribution environment, particularly biologic in-office injectables in the United States.
  • Understanding of coverage, coding (diagnostic, procedural, and product), payment, and reimbursement requirements and policies.
  • Knowledge of Local Coverage Determinations per each regional Medicare Administrative Contractor for all Keenova products.
  • Knowledge of Medicare billing, coding, and appeals; ASP, WAC, sequestration, and interpreting Medicare Explanation of Benefits.
  • Understanding of legislative, legal, and regulatory environments and their potential impact to Keenova.
  • Understanding of the buy-and-bill channel and specialty pharmacy channel.
  • Knowledge of HIPAA requirements and FDA regulations.
  • Understanding of effective communication techniques, including guiding conversations and active listening to encourage patient engagement and understanding.
  • Ability to translate complex clinical, reimbursement, or program-related information into clear, simple, and actionable language.
  • Sound judgment in selecting the appropriate level of detail for different audiences and situations.
  • Ability to synthesize broad information and use it to create positive change for patients and Keenova.
  • Proficiency in business analytics to understand common issues patients encounter and partner with field reimbursement managers when office intervention is appropriate.
  • Ability to work with patients, field reimbursement managers, case managers, and others to develop strategic plans for product access issues.
  • Ability to operate as part of a cross-functional team to collaborate when obstacles arise.
  • Initiative to collaborate with field-based and home office personnel to meet patient needs.
  • Ability to educate external partners proactively on Keenova policies and model the company's vision and core values.
  • Ability to travel up to 30%.
  • Advanced access and reimbursement strategy; complex problem-solving and decision-making; patient advocacy and navigation; cross-functional leadership and influence; strategic insight generation; healthcare system and payer expertise; customer-centric relationship management; operational excellence and execution; and compliance, ethics, and risk management.
Responsibilities
  • Manage patient assistance and reimbursement support services offered to patients, including patient access buy-and-bill products.
  • Coordinate with Keenova patient support services program representatives as needed.
  • Educate patients on the buy-and-bill process, patient assistance, and reimbursement support services.
  • Help patients with buy-and-bill benefit investigation management, specialty pharmacy understanding, expectations, and logistics; reinforce the importance of answering calls throughout the patient journey to avoid delays.
  • Use data to assess acquisition challenges across specialty pharmacies and specialty distributors, identify common logistical issues in accounts, and escalate cases appropriately so field reimbursement managers can develop remediation plans.
  • Assist new patients with reimbursement-process education and information on approved resources for reimbursement, acquisition, and financial assistance.
  • Troubleshoot specialty pharmacy issues with internal and external customers and partner with field reimbursement managers to manage customer-related issues with specialty pharmacies.
  • Work with specialty pharmacies to understand logistical issues, provide approved resources and programs, and communicate to resolve issues.
  • Identify patient knowledge gaps in specialty pharmacy processes and educate patients about their role.
  • Collect, analyze, and synthesize field intelligence on patient access, reimbursement, affordability, healthcare-system dynamics, and patient experience to inform organizational decisions and patient support strategies.
  • Translate patient journey insights, reimbursement trends, and healthcare-system observations into strategic recommendations for organizational priorities, patient support models, and business planning.
  • Identify trends and root causes affecting access and recommend operational enhancements to stakeholders.
  • Serve as a patient access and reimbursement subject-matter expert for the assigned caseload.
  • Provide field intelligence to support organizational decision-making, operational improvements, and patient-centered program evolution.
  • Act as a liaison among patients, providers, specialty pharmacies, and internal stakeholders to improve access effectiveness and patient knowledge.
  • Advise Patient Access leadership on access trends, operational opportunities, and healthcare challenges affecting patient support strategy, resource allocation, and organizational priorities.
  • Support continuous-improvement initiatives to reduce access barriers, accelerate treatment initiation, and enhance patient experience.
  • Contribute to development, refinement, and optimization of patient support programs, educational resources, and access-related initiatives.
  • Evaluate patient journey challenges and recommend solutions to improve patient engagement, treatment initiation, and barrier removal.
  • Participate in pilot programs, launch-readiness activities, and strategic initiatives to enhance patient support effectiveness.
  • Synthesize field observations into actionable business insights for senior leadership.
  • Present access trends, reimbursement challenges, and patient experience findings to internal stakeholders to support data-driven decisions.
  • Identify root causes of patient access barriers and recommend systemic solutions to improve operational performance and patient outcomes.
  • Evaluate patient support program effectiveness and identify opportunities to optimize services, improve patient experience, and enhance organizational performance.
  • Identify opportunities to streamline access pathways, reduce treatment delays, and improve patient outcomes through process improvements and other solutions.
  • Assess the potential impact of market access changes on patient experience and treatment access and recommend mitigation strategies.
  • Recommend and champion process improvements that measurably enhance access outcomes, patient satisfaction, and operational efficiency.
  • Participate in developing patient engagement and support strategies that address evolving patient and healthcare-system needs.
  • Collaborate with leadership to evaluate emerging technologies, digital engagement tools, and service models that may improve access and patient experience.
  • Provide timely, high-quality support to patients, caregivers, and internal stakeholders while maintaining compliance and regulatory boundaries.
  • Identify patients with complex access, reimbursement, affordability, healthcare-literacy, or logistical challenges and develop individualized strategies to support timely treatment initiation and continuity of care.
  • Partner with case managers, specialty pharmacies, provider offices, and field reimbursement managers to coordinate resources, remove barriers, and support positive patient outcomes.
  • Advocate for patients by identifying concerns, obstacles, and unmet needs and escalating issues to facilitate timely resolution.
  • Gather and communicate actionable patient insights about access barriers, affordability challenges, treatment obstacles, and healthcare-literacy concerns to inform program enhancements and organizational decisions.
  • Identify trends affecting patient experience and treatment access and recommend improvements to patient support programs, operational processes, and patient engagement strategies.
  • Help patients and caregivers navigate complex healthcare systems through education, support, resource awareness, and reinforcement of treatment milestones, promoting self-advocacy and informed decisions.
  • Translate patient experiences and access challenges into recommendations that inform patient support strategy, operational priorities, resource allocation, and future program design.
  • Collaborate with internal stakeholders to evaluate patient support services and identify opportunities to improve patient experience, reduce treatment delays, and enhance access effectiveness.
  • Guide internal stakeholders on patient support offerings, patient engagement practices, and appropriate patient interactions consistent with company policies and compliance requirements.
  • Identify recurring patient challenges, unmet needs, and treatment journey obstacles; translate experiences into recommendations for leadership, operations, training, and patient support programs.
  • Identify systemic barriers affecting multiple patients and advocate for organizational changes that improve patient outcomes.
  • Present patient insights and trends to leadership teams to influence program design, resource allocation, and patient support strategy.
  • Recommend process improvements that reduce delays, improve adherence, and enhance the patient experience.
Desired Qualifications
  • Previous experience working with Keenova relationships.
  • Hands-on operational reimbursement experience, both in-house and outsourced.

About the company

Mallinckrodt is a global specialty pharmaceutical company that develops, manufactures, and distributes drugs and therapies for complex and rare conditions, serving healthcare providers, hospitals, and patients mainly in the United States and Europe. Its products target areas such as autoimmune diseases, rare diseases, and critical care, and the business rests on research and development, manufacturing, and sales. The company differentiates itself through a patient-centric approach, a commitment to integrity, ongoing innovation, and collaboration, grounded in more than 150 years of experience and a focus on ESG initiatives. Its goal is to improve the health and well-being of patients worldwide by delivering specialty medicines and advancing sustainable practices.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

Hazelwood, Missouri

Founded

1867

Get referred to Mallinckrodt

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Q2 2026 net sales from continuing operations reached $517 million, up $253 million year-over-year.
  • Keenova reported $25 million synergy capture in Q2 2026, targeting $100 million this year.
  • XIAFLEX plantar fibromatosis Phase 3 was positive July 8, 2026, supporting a Q4 submission.

What critics are saying

  • Maine DEP sued Mallinckrodt on August 25, 2026 over Orrington cleanup failures.
  • The court complaint demands soil removal, sewer-line excavation, penalties, and compliance within 30 days.
  • Environmental liabilities plus recurring litigation threaten cash, management attention, and creditor confidence through 2026.

What makes Mallinckrodt unique

  • Keenova's Acthar Gel and XIAFLEX delivered $355 million quarterly sales in Q2 2026.
  • July 2025 Endo merger created branded specialty depth plus generics and injectables separation.
  • Christiana Stamoulis joined September 22, 2025, adding M&A and integration discipline.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Performance Bonus
  • Relocation Assistance

Growth & Insights and Company News

6 month growth

-6%

1 year growth

-5%

2 year growth

-5%
Maine Morning Star
Aug 27th, 2026
Maine DEP sues Mallinckrodt over failures to clean up contaminated Orrington site.

Maine DEP sues Mallinckrodt over failures to clean up contaminated Orrington site. The Department of Environmental Protection has filed a lawsuit against Mallinckrodt US LLC, accusing the company of failing to clean up mercury contamination at its site in Orrington. The department filed the complaint in Penobscot Superior Court Tuesday, and in court records the department said the company has stopped "meaningful work" at the site despite department orders and notices of violations. Jesse Graham is the co-director of the Maine People's Alliance - which, independent from the state enforcement actions, sued Mallinckrodt over the contamination in federal court in 2000. "We have for a long time been calling for the thorough cleanup of that site, and we have definitely been disappointed that Mallinckrodt has not cleaned it up to the standards that the Maine DEP has set," Graham said. "We fully support the Maine DEP continuing to pressure them and whatever legal tactics they need to do to compel them to finish and do a thorough cleanup of all the pollution that Mallinckrodt has left on the site." Considered the most contaminated site in Maine, the property is the former HoltraChem chloralkali manufacturing facility. Located adjacent to the Penobscot River, the facility operated from 1967 through 2000, and manufactured caustic soda, chlorine bleach and pesticides. In court documents, the department said Mallinckrodt has complained about the difficulties and high costs of cleaning up the site. But, the department said, "this is no excuse for Mallinckrodt's ongoing failure to adhere to the cleanup standards and other requirements of the orders." The department is asking the court for civil penalties, and to order Mallinckrodt to comply with all department orders and submit a plan to remove all soil and solid materials from the site. Attempts to reach someone who could speak on behalf of Mallinckrodt were unsuccessful. The DEP and the U.S. Environmental Protection Agency first began pursuing clean up at the site in the mid-1980s, including negotiations with the company in 2002. But after failing to reach an agreement, in 2008 the department issued a unilateral cleanup order for the site. But Mallinckrodt appealed that order, first to the Board of Environmental Protection, and then in state courts. Ultimately, the state supreme court upheld the department's order in 2014. The department issued notices of violations to Mallinckrodt in May and October of 2025, over the ongoing issues, but said the company still failed to address the shortcomings of their proposed cleanup plans. There is also the federal court case filed by the Maine People's Alliance, which is separate from the state proceedings involving the department. In 2022, Mallinckrodt settled the federal case, and agreed to pay at least $187 million to address mercury pollution in the Penobscot River. Graham said some of that agreed-up work is underway now, as Mallinckrodt adds sand to several coves along the river with high levels of mercury, a process known as "capping."

Charter Communications
Aug 27th, 2026
DEP sues to compel cleanup of 'most contaminated site in Maine'

DEP sues to compel cleanup of 'most contaminated site in Maine' BY Susan Cover Maine PUBLISHED 10:13 AM ET Aug. 27, 2026 AUGUSTA - State officials are escalating action against a company they say has failed to clean up "the most contaminated site in Maine" after more than 20 years of lawsuits. The Maine Department of Environmental Protection filed a formal complaint Tuesday in Penobscot County Superior Court against Mallinckrodt US LLC. The state alleges that the company has failed to clean up the former HoltraChem site on the Penobscot River in Orrington. The site "discharged to the environment tons of mercury and thousands of tons of mercury-contaminated brine-sludge, substances that are defined as hazardous wastes," according to the lawsuit. The facility made chemicals commonly used in the pulp and paper industry, according to DEP. It operated under various owners from 1967 to 2000. The company did not respond to a request for comment. The suit says the facility covered about 235 acres near the river, 77 of which were affected by the production. The site included five landfills, a manufacturing facility and waste piles. In the mid-1980s, the U.S. Environmental Protection Agency and the state began investigating the site and calling for remediation. According to the suit, in 2000, the Maine People's Alliance and the Natural Resources Defense Council filed a lawsuit against the company alleging that the company "discharged mercury from the site into the Penobscot River and that these discharges resulted in an imminent and substantial danger to public health and the environment." A court ordered the company to come up with a remediation plan. The latest lawsuit asks the court to remove contaminated soil and industrial sewer lines, assess civil penalties and require the company to comply with all DEP orders.

Portland Press Herald
Aug 25th, 2026
Maine DEP sues company over cleanup of contaminated Orrington site.

Maine DEP sues company over cleanup of contaminated Orrington site. Mallinckrodt US LLC operated a chemical manufacturing plant along the Penobscot River in Orrington that discharged up to a dozen metric tons of mercury in the late 1960s and early 1970s. Community: Posted 7:54 PM Updated at 7:54 PM The Maine Department of Environmental Protection is suing the owners of a site in Orrington, alleging they've failed to properly clean up contamination. The Maine DEP announced the legal action in Penobscot Superior Court against Mallinckrodt US LLC on Tuesday. The department is seeking injunctive relief and civil penalties. The company operated a chemical manufacturing plant along the Penobscot River in Orrington between 1967 and 1982. While under Mallinckrodt's control, the site discharged between six and 12 metric tons of mercury in the late 1960s and early 1970s, according to one court-ordered study. Please add a subscription to your account to access this story. Choose a plan to keep reading. Starter Digital $1 for 4 weeks * | 4 weeks of access for $1 * | Full access to our websites, ePapers and app * | Newsletters, archives, puzzles and games * | In-depth reporting, investigations and must-read stories * | Share access with up to four other people in your household Annual Digital $99 per year Billed annually - Save 56% * | One year of access for $99 * | Full access to our websites, ePapers and app * | In-depth reporting, investigations and must-read stories * | Share access with up to four other people in your household

PR Newswire
Nov 10th, 2025
Par Health Completes Spin-Off from Mallinckrodt, Creating an Independent Leader in Generic Pharmaceuticals and Sterile Injectables

Launches as Top 15 U.S. Generic Drug Manufacturer, Largest U.S. Producer of Active Pharmaceutical Ingredients and Premier U.S. Producer of Sterile Injectables...

Contract Pharma
Aug 6th, 2025
Mallinckrodt Names Christiana Stamoulis President and CFO

Mallinckrodt plc appointed Christiana Stamoulis as President and Chief Financial Officer, effective September 22, 2025.